Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 9Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Leukemia 1Inflammatory Breast Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Disease Progression 1Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Fulvestrant 3Everolimus 3Cetuximab 3PX-866 2Alpelisib 2venetoclax 1tivozanib 1tipifarnib 1serabelisib 1sapanisertib 1ribociclib 1pembrolizumab 1palbociclib 1neratinib 1exemestane 1cemiplimab 1abemaciclib 1Trimetazidine 1Tamoxifen 1STX-478 1Metformin 1Letrozole 1Irinotecan 1Imlunestrant 1Gemcitabine 1Docetaxel 1Capecitabine 1CB-839 1CA-4948 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hereditary Sensory and Autonomic Neuropathies × neratinib × Clear all
NCT01960023 2021-10-27

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

NSABP Foundation Inc

Phase 1/2 Withdrawn
Gastrointestinal

Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡